Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 58Leukemia 52Lymphoma 37Myelodysplastic Syndromes 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Lymphoma, Non-Hodgkin 22Hodgkin Disease 22Leukemia, Myeloid, Acute 18Multiple Myeloma 17Myeloproliferative Disorders 14Recurrence 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, T-Cell, Peripheral 10Lymphoma, Follicular 10Congenital Abnormalities 10Neoplasms, Plasma Cell 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Hematologic Neoplasms 9Burkitt Lymphoma 9Anemia, Aplastic 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Waldenstrom Macroglobulinemia 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, T-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Graft vs Host Disease 7Sezary Syndrome 6Primary Myelofibrosis 6

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Alemtuzumab × Clear all
NCT00983528 2020-08-12

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

University of California, San Diego

Phase 1/2 Terminated
6 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00895739 2013-08-12

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
Classical hematology

Anemia, Aplastic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡